BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Teva Pharmaceutical Industries Limited (TEVA) Exercises Option to Invest $170 Million in Andromeda


6/17/2010 6:32:58 AM

YAVNE, Israel, June 17, 2010 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. announces that Teva Pharmaceutical Industries Ltd. decided to exercise its option to invest in Andromeda Biotech Ltd. ("Andromeda") at a company per-money valuation of 170 million US dollars.

Teva exclusively licensed Andromeda's lead product, DiaPep277(R), for the treatment of Type 1 Diabetes and received worldwide marketing rights for the product.

Pursuant to the exercise of the option, Teva and Clal Biotechnology Industries (CBI) will invest an additional total of 17.5 million US dollars in Andromeda (11.9 M US$ by Teva, 5.6 M US$ by CBI).

This investment will be utilized by Andromeda to perform DIA-AID 2, a confirmatory Phase III clinical study using DiaPep277(R) for the treatment of newly diagnosed Type 1 Diabetes patients.

DIA-AID 2 will include 450 patients 20-45 years of age. The study is double-blind, placebo-controlled with a treatment period of 24 months. The main goal of the study is to maintain the ability of the pancreas to secrete insulin in patients who receive treatment with DiaPep277(R) compared to the placebo group.

Enrollment of patients has begun in the US as part of a global trial which will be conducted at 100 medical centers in North America, Europe, and Israel.

Shlomo Dagan, CEO of Andromeda, commented, "The current funding will enable Andromeda to continue with our clinical studies using DiaPep277(R) as planned. Our program places Andromeda in the lead to fulfill the unmet need for preserving pancreatic cell function in Type 1 Diabetes patients."

About Andromeda Biotech

Andromeda Biotech Ltd., a subsidiary of Clal Biotechnology Industries Ltd. (TASE:CBI), is focused on the development of an innovative treatment for autoimmune diabetes. Andromeda's DiaPep277(R), currently in Phase III Clinical Studies, is a novel therapeutic approach to treat Type 1 Diabetes. It is a unique peptide derived from the human protein, HSP60, which immunomodulates the immune system, prevents the destruction of pancreatic cells that secrete insulin and preserves their natural function.

Type 1 Diabetes affects approximately 1% of the world's population. To date, there is no therapy capable of preventing the destruction of insulin secreting beta cells. Initially, DiaPep277(R) is targeted to treat newly diagnosed Type 1 Diabetes adult patients with residual insulin secreting cells. Other potential target populations are children with Type 1 Diabetes, patients with a high risk of developing Type 1 Diabetes, and Type 1 Diabetes patients with slow progressing disease.

For more information about Andromeda Biotech please visit our site: (www.andromedabio.com)

Contact:

Andromeda Biotech Ltd. Shlomo Dagan, CEO +972 8 938 7777 info@andromedabio.com


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->